Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action
Executive Summary
Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.
You may also be interested in...
PBM Vertical Integration Impact Under The Microscope At Senate Hearing
A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.
Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs
Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.
PBM Impact On Off-Patent Industry Condemned At Senate Hearing
Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.